Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome + azacitidine + venetoclax in relapsed/refractory AML (real-world, Tongji Hospital)
ChiCTR2500111194Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Oct 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone in acute myeloid leukemia (AML), sponsored by Tongji Hospital. Primary endpoint: Composite complete remission rate (CRc). Started Oct 2025; status: recruiting.
02
Drugs
mitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500111194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111194.